Clinical Trial Update: Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 feasibility study evaluating derivation of a tumor-tissue–derived vaccine for patients with non-small cell lung cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Snippet

Sponsor: Agenus Inc. | Conditions: Non-Small-Cell Lung Carcinoma, Lung Cancer | Phase 2 | Status: COMPLETED